Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma ; volume:14 ; number:2 ; year:2020 ; pages:367-372
Case reports in gastroenterology ; 14, Heft 2 (2020), 367-372
- Creator
-
Yen, Tsai-Hung
Chang, Chung-Hsin
Shiu, Sz-Iuan
- DOI
-
10.1159/000508583
- URN
-
urn:nbn:de:101:1-2020100101391830756416
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yen, Tsai-Hung
- Chang, Chung-Hsin
- Shiu, Sz-Iuan
Other Objects (12)
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Low-dose nivolumab in advanced hepatocellular carcinoma
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
Lysis
Lysis
Lysis
Lysis.
Lysis
Lysis
Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Low-dose nivolumab in advanced hepatocellular carcinoma
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
Lysis
Lysis
Lysis
Lysis.
Lysis
Lysis
Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Low-dose nivolumab in advanced hepatocellular carcinoma
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
Lysis
Lysis
Lysis
Lysis.
Lysis
Lysis
Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma